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Purpose: Tumor necrosis factor alpha (TNF-α), a macrophage/monocyte derived pluripotent 
cytokine is associated with tissue ischemia, neuronal damage and remodeling. The physiologi-
cal level of TNF-α in aqueous humor of normal and glaucomatous eyes is unknown. In this 
study, we evaluated the TNF-α levels in aqueous in patients with primary open angle glaucoma 
(POAG) and compared them to controls. 
Methods: 50–100 µL of undiluted aqueous humor samples were obtained from eyes of 32 
POAG patients who underwent cataract extraction, trabeculectomy or aqueous shunt   implantation. 
Controls were obtained from 32 normal subjects who underwent routine cataract surgery. TNF-α 
levels were quantified using singleplex bead immunoassay analysis.
Results: The average TNF-α level in POAG samples was 2.72 ± 1.5 pg/mL (mean ± SD). 
The average TNF-α level in normal samples was 1.59 ± 0.46 pg/mL (mean ± SD). Signifi-
cant increase of TNF-α levels in POAG samples was noted in comparison to normal samples 
(P , 0.001).
Conclusion: TNF-α levels are elevated in aqueous in patients with POAG compared to normal 
subjects based on highly sensitive Luminex® bead immunoassay and may be a reliable biomarker 
in the progression of glaucoma.
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Introduction
Tumor necrosis factor alpha (TNF-α), a macrophage/monocyte derived pluripotent 
cytokine, is associated with tissue ischemia, neuronal damage, and remodeling,1 and 
increased levels signify neuronal damage after brain trauma.2,3
TNF-α mRNA is upregulated in the retina, with retinal ganglion cell and oligoden-
drite cell loss and consecutive optic atrophy, in a mouse model of glaucoma.4 Elevated 
TNF-α levels in aqueous in this model was attributed to release from damaged retinal 
ganglion cells (RGC) and oligodendrocytes secondary to high intraocular pressure.5 
In humans, immunohistochemical analysis revealed elevated TNF-α expression in the 
optic nerve and the retina of glaucomatous eyes.6,7 However, the physiological level 
of TNF-α in aqueous humor of normal and glaucomatous eyes is unknown.
Estimation of TNF-α may serve as a biomarker in both undiagnosed early 
glaucoma as well as in primary open angle glaucoma (POAG). Additionally, 
evaluating TNF-α levels in glaucoma patients may also help monitor disease pro-
gression and the effectiveness of therapy. We evaluated TNF-α levels in aqueous 
samples of patients with POAG and compared them to controls with singleplex 
bead immunoassay.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Methods
subjects
Our study group consisted of 32 eyes belonging to 32 POAG 
patients (mean age ± SD, 68.6 ± 10.7 years; male/female, 
17/15) who underwent cataract extraction, trabeculectomy, 
or aqueous shunt implantation at the University of Florida, 
Jacksonville. Patients with secondary etiologies, such as 
pseudoexfoliation or pigmentary glaucoma, were excluded 
from the study. Thirty-two normal subjects (mean age ± SD, 
70.3 ± 10.3 years; male/female, 13/19), who underwent 
routine cataract surgery, acted as controls. Subjects in both 
groups with diabetes, macular degeneration, or systemic 
inflammatory conditions were excluded. All study partici-
pants underwent a comprehensive ophthalmic examination, 
including visual acuity, measurement of intraocular pressure, 
slit lamp examination, and fundus biomicroscopy. At the time 
of surgery, all patients with glaucoma were being treated with 
intraocular pressure lowering agents.
Aqueous sample collection
Aqueous sample collections were performed using a stan-
dard sterilization procedure. Sample collection protocol was 
approved by the institutional review board at the University 
of Florida, Jacksonville. Fifty to 100 µL of undiluted aqueous 
humor samples were collected, from each eye, in a tuberculin 
syringe prior to the beginning of surgery. Inadvertent touch-
ing of intraocular tissues was avoided to prevent contamina-
tion of aqueous samples with blood. After collection, samples 
were stored at -80°C.
Use of immunobead assay for TnF-α 
analysis
Samples were diluted 1:2 and processed for TNF-α analysis 
using singleplex bead immunoassay (Invitrogen Corporation, 
USA). Standards were reconstituted and serially diluted, per 
the manufacturer’s instructions. To each well of a 96-well 
microtiter plate, 25 µL of bead and wash solutions were 
added and incubated for 30 seconds. After the incubation 
time, supernatant was aspirated, using vacuum manifold; 
50 µL of incubation buffer were added to each well, followed 
by 50 µL of assay diluent and 50 µL of the aqueous sample. 
Diluted standards were added to the designated wells and 
the plate was incubated for 2 hours at room temperature 
on an orbital shaker at 250–500 rpm. After incubation, the 
liquid was removed and the excess beads were washed off. 
Furthermore, 100 µL of detector antibody was added to each 
well and incubated on an orbital shaker at room temperature 
for 1 hour.
Excess detector antibodies were removed, followed by 
the addition of substrate complex (S-RPE, Streptavidin 
R-Phycoerythrin), and the fluorescence was measured using 
the Luminex 100™ IS fluoroanalyzer (Luminex Inc., Austin, 
TX) after 30 minutes of incubation at room temperature. 
For each reaction, both negative and positive controls were 
included on the microtiter plate. To ensure proper assay, a 
known concentration of human recombinant TNF-α was 
included in each run as a positive control.
Analysis of TnF-α levels
A graphical plot was constructed, using standard concentra-
tion against standard fluorescence. The curve fitting linear 
regression algorithm was performed using GraphPad InStat 
data analysis software (Graphpad, San Diego, CA). The 
concentration of TNF-α level was extracted from standard 
curve and expressed as pg/mL. The effect of dilution was 
considered in determining the final values.
statistical analysis
Statistical analysis was performed with GraphPad InStat and 
Minitab® 13 (Minitab, State College, PA) statistical packages. 
A t-test was used to compare the intergroup variation in 
TNF-α levels between normal and glaucoma samples. A 
P-value of ,0.05 was considered statistically significant.
Results
TNF-α levels were determined in aqueous of 32 glau-
comatous eyes and 32 control eyes using a highly sensitive 
microparticle bead based immunoassay. To ensure the accu-
racy of the assay, 25 to 100 pg/mL of known concentration 
of human recombinant TNF-α was used in each assay as 
internal control.
The mean age of glaucoma patients was 68.6 ± 10.7 years 
and that of the controls was 70.3 ± 10.3 years. Among the 
glaucoma samples, 17 patients were male and 15 patients 
were female and in the controls, 13 were male and 19 were 
female. All glaucoma samples were from POAG patients 
with varying disease severity. The glaucoma samples were 
well matched to control samples in age and gender with no 
significant difference (Table 1).
The average TNF-α level observed in glaucoma sam-
ples was 2.72 ± 1.5 pg/mL (mean ± SD), with a range of 
1.25 to 9.0 pg/mL. The average TNF-α level observed in normal 
samples was 1.59 ± 0.46 pg/mL (mean ± SD), with a range of 
0.806 to 2.456 pg/mL (Figure 1). We observed a significant 
increase in TNF-α levels in the glaucomatous samples in com-
parison to the normal samples (P , 0.001, t-test) (Figure 2).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Discussion
Glaucoma, a common cause of blindness that affects   millions 
of people, is characterized by optic nerve atrophy from 
progressive apoptotic neuronal degeneration secondary to 
elevated intraocular pressure (IOP) over a long period of 
time. Retinal ganglion cells, in response to stress mediated 
through elevated IOP, undergo apoptosis with consecutive 
atrophy.
Cytokine release and oxidative stress contribute to glau-
comatous degeneration.8 TNF-α, a potent immunomodula-
tory cytokine, is upregulated in a patient with posttraumatic 
brain injury.1,2 Poor outcome is associated with elevated 
levels, while inhibition of the TNF-α release limits brain 
damage.3 TNF-α acts on TNF-α receptor 1 (p55) and medi-
ates apoptosis through a caspase-induced pathway. The addi-
tion of exogenous TNF-α following ischemic cerebral injury 
exacerbated neuronal damage, while blocking TNF-α was 
found to be neuroprotective in a rat model.3
In the glaucomatous eye, an upregulation of TNF-α pro-
tein, an elevated TNF-α gene expression in glial cells, and 
a TNF-α receptor 1 in retinal ganglion cells, were noted.7 
Intraocular pressure induced apoptosis of retinal ganglion 
cells (RGC), through caspase-3 and caspase-8 activation.9 
In animal models, TNF-α induced apoptosis was inhibited 
with a TNF-α neutralizing antibody.5
Neurodegenerative disorders, such as Parkinson’s 
disease,10 Alzheimer’s disease,11 and multiple sclerosis,12 
have elevated levels of TNF-α. The pathogenesis of these 
disorders, as well as glaucoma, is a result of a neuroinflam-
matory process.13–15 Pro-inflammatory cytokines, such as 
TNF-α, may contribute to this process.
In a previous study by Sawada et al,16 TNF-α was evalu-
ated in aqueous samples of 84 glaucoma-affected eyes and 
79 eyes from the control group, using an enzyme-linked 
immunosorbent assay (ELISA). TNF-α was detected in 
only 19 eyes, with an overall increased rate of detection 
in glaucomatous eyes compared to control eyes. However, 
the slightly elevated TNF-α aqueous levels in POAG and 
normal tension glaucoma were not found to be statistically 
significant, while those with exfoliation glaucoma showed 
Table 1 Demographic data of subjects with glaucoma and normal 
samples
Normal (n = 32) Glaucoma (n = 32) χ2 test P- Value
sex, male 13 17
sex, female 19 15 χ2 (P = 0.3)
Age (40–70) 18 16
Age (70–90) 14 16 χ2 (P = 0.6)
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Figure 1 TnF-α levels in normal and glaucoma samples. The sample number is shown on the X-axis and the TnF-α levels expressed in pg/mL are shown on the Y-axis.
Abbreviation: TnF-α, tumor necrosis factor alpha.Clinical Ophthalmology
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a statistically significant increase compared to control eyes. 
Kuchtey et al17 further elucidated TNF-α levels in aqueous 
humor, with multiplex microparticle-based immunoassay, but 
were unable to detect TNF-α in glaucomatous eyes.
In the present study, the more sensitive singleplex bead 
immunoassay was used to determine values in normal eyes 
as well as eyes with primary open-angle glaucoma. We found 
the average level of TNF-α in normal samples to be 1.09 pg/
mL, compared to 3.35 pg/mL in glaucomatous eyes. Though 
most of the patients in this study had well-controlled IOP, seven 
patients had advanced glaucoma and underwent trabeculectomy, 
or valve placement, for IOP refractory to medical therapy.
Though vitreous levels of TNF-α are likely to be higher, 
due to its proximity to the retina, a small proportion of TNF-α 
diffuses to the aqueous humor. Sensitive immunoassay that 
detects these levels may identify the presence of glaucoma-
tous damage in a quantitative manner. Using this bead based 
immunoassay, the TNF-α levels can be estimated even at 
low levels. Factors such as severity of glaucoma and use of 
topical medications may also influence TNF-α levels. This 
aspect of the study must be further evaluated in a larger 
cohort study.
In summary, TNF-α levels were elevated in aqueous in 
patients with POAG compared to normal subjects, based on 
highly sensitive Luminex® bead immunoassay.
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Figure 2 Comparative analysis of TnF-α levels between normal and glaucoma 
samples. mean values are represented by solid circles. 
Note: Significant difference was observed between normal versus glaucoma samples 
(P , 0.001).
Abbreviation: TnF-α, tumor necrosis factor alpha.